GLT8D2

Across TCGA pan-cancer cohorts, GLT8D2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GLT8D2 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GLT8D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLT8D2 expression acts as an unfavorable survival marker.

LUSC, KICH, and GBM are the cancer types where GLT8D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.213	0.766	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
GBM	DFS	Median	All	0.034	0.245	<.001	12	view →
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	OS	Median	All	0.167	0.704	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GLT8D2–LUSC (OS)

Open the LUSC breakdown →